Titration of Medications after Acute Heart Failure is Safe, Tolerated, and Effective Regardless of Risk
Andrew P. Ambrosy,Alex J. Chang,Beth Davison,Adriaan Voors,Alain Cohen-Solal,Albertino Damasceno,Antoine Kimmoun,Carolyn S.P. Lam,Christopher Edwards,Daniela Tomasoni,Etienne Gayat,Gerasimos Filippatos,Hadiza Saidu,Jan Biegus,Jelena Celutkiene,Jozine M. Ter Maaten,Kamilė Čerlinskaitė-Bajorė,Karen Sliwa,Koji Takagi,Marco Metra,Maria Novosadova,Marianela Barros,Marianna Adamo,Matteo Pagnesi,Mattia Arrigo,Ovidiu Chioncel,Rafael Diaz,Peter S. Pang,Piotr Ponikowski,Gad Cotter,Alexandre Mebazaa
DOI: https://doi.org/10.1016/j.jchf.2024.04.017
IF: 12.544
2024-05-14
JACC Heart Failure
Abstract:Background Guideline-directed medical therapy decisions may be less affected by single patient variables such as blood pressure or kidney function and more by overall risk profile. In STRONG-HF, high intensity care (HIC) in the form of rapid uptitration of heart failure (HF) guideline-directed medical therapy (GDMT) was effective overall, but the safety, tolerability and efficacy of HIC across the spectrum of HF severity is unknown. Evaluating this with a simple risk-based framework offers an alternative and more clinically translatable approach than traditional subgroup analyses. Objectives To assess safety, tolerability, and efficacy of HIC according to the simple, powerful, and clinically translatable Meta-Analysis Global Group in Chronic (MAGGIC) HF risk score. Methods In STRONG-HF, 1078 patients with acute HF were randomized to HIC (uptitration of treatments to 100% of recommended doses within 2 weeks of discharge and 4 scheduled outpatient visits over the 2 months after discharge) versus usual care (UC). The primary endpoint was the composite of all-cause death or first HF rehospitalization at Day 180. Baseline HF risk profile was determined by the previously validated MAGGIC risk score. Treatment effect was stratified according to MAGGIC risk score both as a categorical and continuous variable. Results Among 1062 patients (98.5%) with complete data for whom a MAGGIC score could be calculated at baseline, GDMT use at baseline was similar across MAGGIC tertiles. Overall GDMT prescriptions achieved for individual medication classes were higher in the HIC versus UC group and did not differ by MAGGIC risk score tertiles (interaction non-significant). The incidence of all-cause death or HF readmission at Day 180 was, respectively, 16.3%, 18.9%, and 23.2% for MAGGIC risk score tertiles 1-3. The HIC arm was at lower risk of all-cause death or HF readmission at Day 180 (HR 0.66, 95% CI 0.50-0.86) and this finding was robust across MAGGIC risk score modeled as a categorical (HR 0.51, 0.62, 0.68 in tertile 1, 2, and 3, respectively, (interaction non-significant) for all comparisons) and continuous (p-interaction=NS) variable. The rate of adverse events was higher in the HIC group, but this observation did not differ based on MAGGIC risk score tertile (interaction non-significant). Conclusions HIC led to better use of GDMT and lower HF-related morbidity and mortality compared to UC regardless of underlying HF risk profile.
cardiac & cardiovascular systems